1-3 of 3
Karin Garming-Legert
Close
Sort by
Journal Articles

Thymic Function Predicts Response to Mesenchymal Stromal Cell Treatment in Chronic GvHD: A Phase II Clinical Study

Erik Boberg, Lena Von Bahr, MD PhD, Nina Heldring, PhD, Gabriel Afram, MD, Ellen Iacobaeus, MD PhD, Carina Lindström, RN, Karin Garming-Legert, DMD, PhD, Per Ljungman, Rachael Sugars, PhD, Lindsay Davies, MD PhD, Nadir Kadri, PhD, Katarina Le Blanc, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3253.
https://doi.org/10.1182/blood.V130.Suppl_1.3253.3253
Published: 2017
Journal Articles

Treatment of Chronic GvHD with Mesenchymal Stromal Cells Induces Durable Responses; A Phase II Study

Lena Von Bahr, MD, Lindsay Davies, PhD, Gabriel Afram, MD, Carina Modin, Karin Garming-Legert, PhD, Hans Hägglund, MD PhD, Per T. Ljungman, MD PhD, Katarina Le Blanc, MD, PhD
Journal: Blood
Blood (2015) 126 (23): 3138.
https://doi.org/10.1182/blood.V126.23.3138.3138
Published: 2015
Journal Articles

Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease

J. Marius Munneke, Andreas T. Björklund, Jenny M. Mjösberg, Karin Garming-Legert, Jochem H. Bernink, Bianca Blom, Cynthia Huisman, Marinus H. J. van Oers, Hergen Spits, Karl-Johan Malmberg, Mette D. Hazenberg
Journal: Blood
Blood (2014) 124 (5): 812–821.
https://doi.org/10.1182/blood-2013-11-536888
Published: 2014
Includes: Supplemental data